Drug Information

Drug General Information
Drug ID
D07URD
Former ID
DIB004804
Drug Name
PRX-102
Synonyms
Galactosidase enzyme replacement therapy (Fabry disease), Protalix
Indication Fabry's disease [ICD9: 272.7; ICD10:E75.2] Phase 1/2 [524520]
Company
Protalix biotherapeutics
Target and Pathway
Target(s) Alpha-galactosidase A Target Info Modulator [532932]
KEGG Pathway Galactose metabolism
Glycerolipid metabolism
Sphingolipid metabolism
Glycosphingolipid biosynthesis - globo series
Lysosome
PathWhiz Pathway Sphingolipid Metabolism
Galactose Metabolism
Reactome Glycosphingolipid metabolism
WikiPathways Sphingolipid metabolism
References
Ref 524520ClinicalTrials.gov (NCT01981720) Extension Study of PRX-102 for 24 Months. U.S. National Institutes of Health.
Ref 532932Characterization of a chemically modified plant cell culture expressed human alpha-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015 Feb;114(2):259-67.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.